Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
- Medicinal cannabis: what next for Brazil? 21-10-2019
- Pharma: A Mexican tradeoff 30-09-2019
- Secondary patents: Moscow mewl 30-09-2019
- The future of precision medicine part 6: reimbursement 08-08-2019
- Shire Pharmaceuticals: A culture of excellence 21-05-2019
Latest generics news
Canada's drug pricing plan prompts backlash
26-10-2020
The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
